Akebia Therapeutics Stock Price, News & Analysis (NASDAQ:AKBA)

$15.36 0.23 (1.52 %)
(As of 11/20/2017 04:00 PM ET)
Previous Close$15.13
Today's Range$14.86 - $15.43
52-Week Range$7.78 - $20.25
Volume315,500 shs
Average Volume514,004 shs
Market Capitalization$726.05 million
P/E RatioN/A
Dividend YieldN/A
Beta0.99

About Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics logoAkebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:AKBA
  • CUSIP: N/A
  • Web: akebia.com
Debt:
  • Current Ratio: 2.21%
  • Quick Ratio: 2.21%
Sales & Book Value:
  • Annual Sales: $1.53 million
  • Price / Sales: 474.55
  • Book Value: $1.78 per share
  • Price / Book: 8.63
Profitability:
  • Trailing EPS: ($3.16)
  • Net Income: ($135,740,000.00)
  • Net Margins: -137.80%
  • Return on Equity: -198.85%
  • Return on Assets: -41.16%
Misc:
  • Employees: 90
  • Outstanding Shares: 47,270,000
 

Frequently Asked Questions for Akebia Therapeutics (NASDAQ:AKBA)

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.56) by $0.07. The biopharmaceutical company earned $41.28 million during the quarter, compared to the consensus estimate of $34 million. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. View Akebia Therapeutics' Earnings History.

Where is Akebia Therapeutics' stock going? Where will Akebia Therapeutics' stock price be in 2017?

6 brokerages have issued twelve-month price objectives for Akebia Therapeutics' shares. Their forecasts range from $17.00 to $25.00. On average, they anticipate Akebia Therapeutics' stock price to reach $22.00 in the next year. View Analyst Ratings for Akebia Therapeutics.

What are Wall Street analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:

  • 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (11/13/2017)
  • 2. Aegis analysts commented, "We expect totals sales for Shire’s HAE franchise to reach $1.9B by 2021. Consensus is only at $1.8B. We think Lanadelumab has peak sales potential of $2B worldwide and the entire HAE franchise has peak sales potential of $2.3B. Shire expects to launch Lanadelumab in 2H18. The product will have a 8-month review at the FDA." (6/30/2017)

Who are some of Akebia Therapeutics' key competitors?

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the folowing people:

  • Muneer A. Satter J.D., Independent Chairman of the Board (Age 56)
  • John P. Butler, President, Chief Executive Officer, Director (Age 52)
  • Jason A. Amello, Chief Financial Officer, Senior Vice President, Treasurer (Age 48)
  • Nicole R. Hadas, Senior Vice President, General Counsel, Secretary (Age 44)
  • Michel Dahan, Senior Vice President and Chief Business Officer (Age 38)
  • Rita Jain M.D., Senior Vice President, Chief Medical Officer
  • Karen Tubridy, Senior Vice President, Chief Development Officer (Age 54)
  • Scott A. Canute, Independent Director (Age 57)
  • Michael D. Clayman M.D., Independent Director (Age 65)
  • Maxine Gowen Ph.D., Independent Director (Age 59)

Who owns Akebia Therapeutics stock?

Akebia Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Eagle Asset Management Inc. (6.46%), Perceptive Advisors LLC (3.45%), First Manhattan Co. (4.99%), Schwab Charles Investment Management Inc. (0.50%), EAM Investors LLC (0.50%) and Bank of New York Mellon Corp (0.48%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.

Who sold Akebia Therapeutics stock? Who is selling Akebia Therapeutics stock?

Akebia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc. and First Manhattan Co.. Company insiders that have sold Akebia Therapeutics company stock in the last year include Duane Nash, Michel Dahan and Nicole R Hadas. View Insider Buying and Selling for Akebia Therapeutics.

Who bought Akebia Therapeutics stock? Who is buying Akebia Therapeutics stock?

Akebia Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, 361 Capital LLC, OxFORD Asset Management LLP, American Century Companies Inc., Mutual of America Capital Management LLC, Ameriprise Financial Inc., Los Angeles Capital Management & Equity Research Inc. and Prudential Financial Inc.. View Insider Buying and Selling for Akebia Therapeutics.

How do I buy Akebia Therapeutics stock?

Shares of Akebia Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of Akebia Therapeutics stock can currently be purchased for approximately $15.36.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $726.05 million and generates $1.53 million in revenue each year. The biopharmaceutical company earns ($135,740,000.00) in net income (profit) each year or ($3.16) on an earnings per share basis. Akebia Therapeutics employs 90 workers across the globe.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 1st St Ste 1100, CAMBRIDGE, MA 02142-1292, United States. The biopharmaceutical company can be reached via phone at +1-617-8712098 or via email at [email protected]


MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  311
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Akebia Therapeutics (NASDAQ:AKBA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $22.00 (43.23% upside)

Consensus Price Target History for Akebia Therapeutics (NASDAQ:AKBA)

Price Target History for Akebia Therapeutics (NASDAQ:AKBA)

Analysts' Ratings History for Akebia Therapeutics (NASDAQ:AKBA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017HC WainwrightReiterated RatingBuy$24.00N/AView Rating Details
11/9/2017MizuhoReiterated RatingBuy$24.00N/AView Rating Details
11/2/2017Royal Bank Of CanadaReiterated RatingHold$17.00N/AView Rating Details
6/30/2017AegisReiterated RatingBuyHighView Rating Details
5/17/2017Needham & Company LLCReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
4/26/2017JMP SecuritiesBoost Price TargetOutperform$19.00 -> $21.00HighView Rating Details
9/29/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
8/9/2016Credit Suisse GroupReiterated RatingHold$8.00N/AView Rating Details
5/8/2016Morgan StanleyReiterated RatingBuyN/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$24.00 -> $16.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Akebia Therapeutics (NASDAQ:AKBA)

Earnings by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Earnings History by Quarter for Akebia Therapeutics (NASDAQ AKBA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.56)($0.49)$34.00 million$41.28 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.89)($0.53)$26.50 million$28.52 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.15)($1.15)$16.50 million$20.87 millionViewN/AView Earnings Details
3/6/2017Q4 2016$0.77($0.99)$125.00 million$1.54 millionViewListenView Earnings Details
11/9/2016Q3($1.09)($0.96)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.57)($0.95)$6.00 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.43)($0.70)$9.00 millionViewN/AView Earnings Details
3/14/2016Q415($0.28)($0.66)$11.60 millionViewListenView Earnings Details
11/9/2015Q3($0.52)($0.68)ViewN/AView Earnings Details
8/11/2015Q215($0.51)($0.40)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.57)($0.53)ViewN/AView Earnings Details
3/4/2015Q414($0.66)($0.52)ViewN/AView Earnings Details
11/10/2014Q314($0.45)($0.47)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.34)($0.39)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Akebia Therapeutics (NASDAQ:AKBA)
Current Year EPS Consensus Estimate: $-2.25 EPS
Next Year EPS Consensus Estimate: $-0.87 EPS

Dividends

Dividend History for Akebia Therapeutics (NASDAQ:AKBA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Akebia Therapeutics (NASDAQ AKBA)

Insider Ownership Percentage: 8.67%
Institutional Ownership Percentage: 60.09%
Insider Trades by Quarter for Akebia Therapeutics (NASDAQ:AKBA)
Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Insider Trades by Quarter for Akebia Therapeutics (NASDAQ AKBA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Duane NashDirectorSell1,188$19.64$23,332.32View SEC Filing  
10/2/2017Michel DahanSVPSell1,398$19.64$27,456.72View SEC Filing  
9/28/2017Michel DahanSVPSell5,000$19.30$96,500.00View SEC Filing  
8/15/2017Michel DahanSVPSell5,000$15.00$75,000.00View SEC Filing  
7/5/2017Muneer A SatterDirectorBuy1,034,482$14.50$14,999,989.00View SEC Filing  
7/3/2017Duane NashDirectorSell990$14.27$14,127.30View SEC Filing  
7/3/2017Nicole R. HadasSVPSell1,554$14.26$22,160.04View SEC Filing  
4/3/2017Duane NashDirectorSell991$9.20$9,117.20View SEC Filing  
4/3/2017Nicole R HadasSVPSell1,556$9.18$14,284.08View SEC Filing  
1/3/2017Duane NashDirectorSell1,980$10.46$20,710.80View SEC Filing  
1/1/2017Nicole R. HadasSVPSell1,810$10.49$18,986.90View SEC Filing  
7/6/2016Duane NashDirectorSell1,980$7.48$14,810.40View SEC Filing  
7/5/2016Nicole R. HadasSVPSell1,557$7.47$11,630.79View SEC Filing  
4/4/2016Michel DahanSVPSell1,401$9.41$13,183.41View SEC Filing  
10/2/2015Nicole R HadasSVPSell1,484$8.67$12,866.28View SEC Filing  
7/2/2015Nicole R HadasSVPSell1,484$9.54$14,157.36View SEC Filing  
4/22/2015Muneer A SatterDirectorBuy420,000$8.25$3,465,000.00View SEC Filing  
4/2/2015Nicole R HadasSVPSell1,483$9.09$13,480.47View SEC Filing  
1/2/2015Nicole R HadasVPSell1,715$11.46$19,653.90View SEC Filing  
12/29/2014John P ButlerCEOBuy1,000$11.57$11,570.00View SEC Filing  
12/26/2014Duane NashDirectorSell11,933$11.23$134,007.59View SEC Filing  
12/22/2014John P ButlerCEOBuy1,000$11.92$11,920.00View SEC Filing  
12/15/2014John P ButlerCEOBuy1,000$11.34$11,340.00View SEC Filing  
12/2/2014Ronald C Renaud JrDirectorBuy5,000$11.92$59,600.00View SEC Filing  
11/26/2014Jason AmelloCFOBuy1,000$13.22$13,220.00View SEC Filing  
11/25/2014Muneer A SatterDirectorBuy5,000$13.18$65,900.00View SEC Filing  
11/24/2014Muneer A SatterDirectorBuy5,000$13.88$69,400.00View SEC Filing  
11/21/2014Muneer A SatterDirectorBuy5,000$14.73$73,650.00View SEC Filing  
11/20/2014Muneer A SatterDirectorBuy5,000$14.70$73,500.00View SEC Filing  
11/19/2014Muneer A SatterDirectorBuy5,000$14.85$74,250.00View SEC Filing  
11/18/2014Muneer A SatterDirectorBuy5,000$13.84$69,200.00View SEC Filing  
11/17/2014Muneer A SatterDirectorBuy5,000$12.94$64,700.00View SEC Filing  
11/14/2014Muneer A SatterDirectorBuy5,000$11.91$59,550.00View SEC Filing  
11/13/2014Muneer A SatterDirectorBuy5,000$11.56$57,800.00View SEC Filing  
11/12/2014John P ButlerCEOBuy1,000$10.31$10,310.00View SEC Filing  
11/12/2014Muneer A SatterDirectorBuy5,000$11.90$59,500.00View SEC Filing  
3/25/2014A/S NovoInsiderBuy182,590$17.00$3,104,030.00View SEC Filing  
3/25/2014Jason AmelloCFOBuy4,000$17.00$68,000.00View SEC Filing  
3/25/2014John P ButlerCEOBuy13,850$17.00$235,450.00View SEC Filing  
3/25/2014Muneer A SatterDirectorBuy91,295$17.00$1,552,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Akebia Therapeutics (NASDAQ AKBA)

Source:
DateHeadline
Akebia Therapeutics, Inc. (AKBA) Stock Rating Reaffirmed by HC WainwrightAkebia Therapeutics, Inc. (AKBA) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 19 at 6:20 PM
Critical Review: Akebia Therapeutics (AKBA) & Its CompetitorsCritical Review: Akebia Therapeutics (AKBA) & Its Competitors
www.americanbankingnews.com - November 19 at 5:06 PM
Akebia Therapeutics to Participate in Upcoming Investor ConferencesAkebia Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 16 at 10:57 AM
Akebia Therapeutics, Inc. (AKBA) Lifted to Buy at Zacks Investment ResearchAkebia Therapeutics, Inc. (AKBA) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 13 at 8:30 PM
Akebia Therapeutics, Inc. (AKBA) Given Average Recommendation of "Buy" by BrokeragesAkebia Therapeutics, Inc. (AKBA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 12 at 10:20 AM
Akebia Therapeutics Enters Oversold Territory (AKBA)Akebia Therapeutics Enters Oversold Territory (AKBA)
www.thestreet.com - November 9 at 4:41 PM
Akebia Therapeutics, Inc. (AKBA) Releases Quarterly  Earnings Results, Beats Estimates By $0.07 EPSAkebia Therapeutics, Inc. (AKBA) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - November 9 at 2:27 PM
Akebia Therapeutics Announces Third Quarter 2017 Financial ... - Business Wire (press release)Akebia Therapeutics Announces Third Quarter 2017 Financial ... - Business Wire (press release)
www.businesswire.com - November 9 at 4:04 AM
Akebia Therapeutics Announces Third Quarter 2017 Financial ResultsAkebia Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 5:56 PM
Akebia Therapeutics reports 3Q lossAkebia Therapeutics reports 3Q loss
finance.yahoo.com - November 8 at 5:56 PM
Is Akebia Therapeutics Inc’s (AKBA) Liquidity As Good As Its Solvency?Is Akebia Therapeutics Inc’s (AKBA) Liquidity As Good As Its Solvency?
finance.yahoo.com - November 7 at 5:15 PM
Royal Bank Of Canada Reiterates Hold Rating for Akebia Therapeutics, Inc. (AKBA)Royal Bank Of Canada Reiterates Hold Rating for Akebia Therapeutics, Inc. (AKBA)
www.americanbankingnews.com - November 2 at 3:20 PM
Akebia Therapeutics, Inc. (AKBA) Scheduled to Post Quarterly Earnings on TuesdayAkebia Therapeutics, Inc. (AKBA) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 7:44 AM
Akebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : October 27, 2017Akebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : October 27, 2017
finance.yahoo.com - October 27 at 5:48 PM
Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : October 26, 2017Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : October 26, 2017
finance.yahoo.com - October 26 at 11:08 AM
Biotech Stock Performance Review -- Agenus, Akebia Therapeutics ... - PR Newswire (press release)Biotech Stock Performance Review -- Agenus, Akebia Therapeutics ... - PR Newswire (press release)
www.prnewswire.com - October 20 at 10:37 PM
Akebia Therapeutics, Inc. (AKBA) Given Average Rating of "Buy" by AnalystsAkebia Therapeutics, Inc. (AKBA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 18 at 10:30 AM
Acer Therapeutics Welcomes Two New Members to its Board of DirectorsAcer Therapeutics Welcomes Two New Members to its Board of Directors
feeds.benzinga.com - October 12 at 9:25 AM
Akebia Therapeutics, Inc. (AKBA) Downgraded by Zacks Investment Research to HoldAkebia Therapeutics, Inc. (AKBA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - October 10 at 8:56 PM
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - October 5 at 1:09 PM
Akebia Therapeutics, Inc. (AKBA) Director Duane Nash Sells 1,188 SharesAkebia Therapeutics, Inc. (AKBA) Director Duane Nash Sells 1,188 Shares
www.americanbankingnews.com - October 4 at 9:08 PM
Michel Dahan Sells 1,398 Shares of Akebia Therapeutics, Inc. (AKBA) StockMichel Dahan Sells 1,398 Shares of Akebia Therapeutics, Inc. (AKBA) Stock
www.americanbankingnews.com - October 4 at 8:48 PM
Akebia Therapeutics, Inc. (AKBA) Earns Buy Rating from Analysts at MizuhoAkebia Therapeutics, Inc. (AKBA) Earns Buy Rating from Analysts at Mizuho
www.americanbankingnews.com - October 4 at 5:26 PM
Akebia Therapeutics, Inc. (AKBA) SVP Sells $96,500.00 in StockAkebia Therapeutics, Inc. (AKBA) SVP Sells $96,500.00 in Stock
www.americanbankingnews.com - October 2 at 7:42 PM
AKBA Crosses Above Average Analyst TargetAKBA Crosses Above Average Analyst Target
www.thestreet.com - October 2 at 3:30 PM
Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney DiseaseAkebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease
www.businesswire.com - September 27 at 8:11 PM
Akebia Therapeutics, Inc. (AKBA) Receives Average Rating of "Buy" from BrokeragesAkebia Therapeutics, Inc. (AKBA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 23 at 9:08 AM
Ex-Akebia employee suspected of insider trading re-arrestedEx-Akebia employee suspected of insider trading re-arrested
finance.yahoo.com - September 22 at 7:42 PM
Royal Bank Of Canada Reiterates Outperform Rating for Akebia Therapeutics, Inc. (AKBA)Royal Bank Of Canada Reiterates Outperform Rating for Akebia Therapeutics, Inc. (AKBA)
www.americanbankingnews.com - September 16 at 7:18 AM
Akebia Therapeutics, Inc. (AKBA) Now Covered by Royal Bank Of CanadaAkebia Therapeutics, Inc. (AKBA) Now Covered by Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 5:26 PM
Akebia (AKBA) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowAkebia (AKBA) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 9:53 PM
Ultragenyxs Burosumab Positive in Phase II for XLH and TIOUltragenyx's Burosumab Positive in Phase II for XLH and TIO
finance.yahoo.com - September 12 at 3:54 PM
Akebia Reports Inducement Grant Under NASDAQ Listing Rule ... - Business Wire (press release)Akebia Reports Inducement Grant Under NASDAQ Listing Rule ... - Business Wire (press release)
www.businesswire.com - September 9 at 3:31 PM
Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge - Yahoo FinanceWhy Akebia Therapeutics (AKBA) Could Be Positioned for a Surge - Yahoo Finance
finance.yahoo.com - September 6 at 3:38 PM
Akebia to Present at Upcoming Investor ConferencesAkebia to Present at Upcoming Investor Conferences
finance.yahoo.com - September 5 at 4:56 PM
Why Akebia Therapeutics (AKBA) Could Be Positioned for a SurgeWhy Akebia Therapeutics (AKBA) Could Be Positioned for a Surge
finance.yahoo.com - September 5 at 4:56 PM
FDAs Refusal-to-File Letter for Inbrija Pushes Acorda DownFDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down
www.msn.com - August 30 at 4:26 PM
Strength Seen in Catalent (CTLT): Stock Soars 13.9%Strength Seen in Catalent (CTLT): Stock Soars 13.9%
www.zacks.com - August 30 at 4:26 PM
Akebia Therapeutics, Inc. (AKBA) Given Consensus Rating of "Buy" by AnalystsAkebia Therapeutics, Inc. (AKBA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 29 at 10:58 AM
Featured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor ProgramFeatured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program
finance.yahoo.com - August 23 at 3:44 PM
Akebia Therapeutics, Inc. (AKBA) SVP Sells $75,000.00 in StockAkebia Therapeutics, Inc. (AKBA) SVP Sells $75,000.00 in Stock
www.americanbankingnews.com - August 17 at 8:32 PM
Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August 14, 2017Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August 14, 2017
finance.yahoo.com - August 14 at 4:03 PM
Akebia Therapeutics, Inc. (AKBA) Posts  Earnings Results, Beats Expectations By $0.36 EPSAkebia Therapeutics, Inc. (AKBA) Posts Earnings Results, Beats Expectations By $0.36 EPS
www.americanbankingnews.com - August 9 at 4:08 PM
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Rating Reaffirmed by HC WainwrightAkebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - August 9 at 7:40 AM
Akebia Announces Second Quarter 2017 Financial Results - Business Wire (press release)Akebia Announces Second Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - August 8 at 8:42 PM
Akebia Announces Second Quarter 2017 Financial ResultsAkebia Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 8:42 PM
Akebia Therapeutics reports 2Q lossAkebia Therapeutics reports 2Q loss
finance.yahoo.com - August 8 at 8:42 PM
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - August 4 at 9:10 PM
Akebia Therapeutics, Inc. (AKBA) Receives Consensus Recommendation of "Buy" from AnalystsAkebia Therapeutics, Inc. (AKBA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 4 at 10:44 AM
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Scheduled to Post Quarterly Earnings on MondayAkebia Therapeutics, Inc. (NASDAQ:AKBA) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:05 AM

Social Media

Financials

Chart

Akebia Therapeutics (NASDAQ AKBA) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.